Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of 2-AI can be broken down into several components which progressively intensify proportional to dosage.
The general head space of 2-AI is described by many as one of mental stimulation, increased focus, and euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate doses, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
Moderately addictive with high potential for abuse and capable of causing psychological dependence. Users report significant desire to re-dose after a few hours as well as the following day. Chronic use can lead to cravings if use is suddenly stopped.
Physical dependence has not been specifically characterized. While withdrawal effects are mentioned in the context of chronic use, available information primarily addresses psychological rather than physical dependence.
The exact toxic dosage is unknown due to very limited history of human usage.
Abuse at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Research on similar stimulants suggests 5-15% of users experiencing stimulant-induced psychosis may not fully recover, though antipsychotic medications are effective at resolving acute symptoms.
2-Aminoindane emerged on the research chemical market around 2003, becoming available primarily through online vendors as a designer drug. As an amphetamine analogue with stimulant properties, it attracted interest within the research chemical community despite very limited documentation of its…
Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are all illegal.
Scheduled under the government decree on psychoactive substances banned from the consumer market.
2-aminoindane and certain derivatives have been classified as controlled substances since June 4, 2012.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Not specifically controlled at the federal level, meaning possession is generally legal. However, 2-AI may be considered an analogue of amphetamine, in which case purchase, sale, or possession with intent for human consumption could potentially be prosecuted under the Federal Analog Act.
Classified as a controlled substance since October 2015.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production and import with intent to distribute, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalties.
Sweden's public health agency recommended classifying 2-AI as a hazardous substance on June 24, 2019. Current legal status may have changed following this recommendation.
Prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016. Production, supply, and importation are criminal offenses.
